ATE495445T1 - Verfahren und zusammensetzungen in verbindung mit morbus alzheimer - Google Patents
Verfahren und zusammensetzungen in verbindung mit morbus alzheimerInfo
- Publication number
- ATE495445T1 ATE495445T1 AT05788728T AT05788728T ATE495445T1 AT E495445 T1 ATE495445 T1 AT E495445T1 AT 05788728 T AT05788728 T AT 05788728T AT 05788728 T AT05788728 T AT 05788728T AT E495445 T1 ATE495445 T1 AT E495445T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- disease
- methods
- compositions related
- proteins
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0421639.6A GB0421639D0 (en) | 2004-09-29 | 2004-09-29 | Methods and compositions relating to alzheimer's disease |
PCT/GB2005/003756 WO2006035237A2 (en) | 2004-09-29 | 2005-09-29 | Methods and compositions relating to alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE495445T1 true ATE495445T1 (de) | 2011-01-15 |
Family
ID=33397455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05788728T ATE495445T1 (de) | 2004-09-29 | 2005-09-29 | Verfahren und zusammensetzungen in verbindung mit morbus alzheimer |
Country Status (10)
Country | Link |
---|---|
US (2) | US7897361B2 (de) |
EP (3) | EP2354795B1 (de) |
JP (3) | JP5483816B2 (de) |
AT (1) | ATE495445T1 (de) |
AU (1) | AU2005288689B2 (de) |
CA (1) | CA2580532C (de) |
DE (1) | DE602005025897D1 (de) |
DK (1) | DK2354795T3 (de) |
GB (1) | GB0421639D0 (de) |
WO (1) | WO2006035237A2 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0421639D0 (en) * | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
GB0426859D0 (en) * | 2004-12-07 | 2005-01-12 | Proteome Sciences Plc | Diagnosis of neurodegenerative disorders |
GB2428240A (en) | 2005-07-14 | 2007-01-24 | Univ Gen Ve | Diagnostic method for brain damage-related disorders |
US8044179B2 (en) | 2005-09-13 | 2011-10-25 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
GB0701626D0 (en) * | 2007-01-22 | 2007-03-07 | Cambridge Entpr Ltd | Methods and biomarkers for diagnosing and monitoring psychotic disorders |
AT506819B1 (de) | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
US20110263450A1 (en) * | 2008-09-26 | 2011-10-27 | The University Of Melbourne | Alzheimer's disease biomarkers |
IT1392551B1 (it) * | 2008-11-25 | 2012-03-09 | Bioindustry Park Del Canavese S P A | Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica |
WO2010084327A2 (en) | 2009-01-26 | 2010-07-29 | Electrophoretics Limited | Methods |
JP2010271078A (ja) * | 2009-05-19 | 2010-12-02 | Mcbi:Kk | 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法 |
AU2010202926B2 (en) * | 2009-09-11 | 2016-07-14 | Electrophoretics Limited | Markers and methods relating to the assessment of Alzheimer's disease |
AU2010324506B2 (en) | 2009-11-24 | 2015-02-26 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
JP6012923B2 (ja) * | 2010-12-22 | 2016-10-25 | 株式会社Mcbi | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
JP5906519B2 (ja) * | 2011-09-13 | 2016-04-20 | 国立大学法人 熊本大学 | 二次元電気泳動による蛋白質の分離方法 |
WO2013074861A1 (en) * | 2011-11-18 | 2013-05-23 | Alnylam Pharmaceuticals, Inc. | Quantification of transthyretin and its isoforms |
US9822170B2 (en) | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
USRE49625E1 (en) | 2012-03-29 | 2023-08-29 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | Nanoscale process to generate reagents selective for individual protein variants |
EP2831310A4 (de) | 2012-03-29 | 2016-04-06 | Univ Arizona | Nanoskaliges verfahren zum erzeugen von für individuelle proteinvarianten selektiven reagenzien |
EP2834259A4 (de) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | Modifizierte polynukleotide |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
MX358474B (es) | 2012-04-13 | 2018-08-21 | Oasis Diagnostics Corp | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. |
WO2014040042A2 (en) | 2012-09-10 | 2014-03-13 | The Johns Hopkins University | Diagnostic assay for alzheimer's disease |
WO2014055683A1 (en) * | 2012-10-03 | 2014-04-10 | The Research Foundation For The State University Of New York | Spectroscopic method for alzheimer's disease diagnosis |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
DK2962100T3 (da) * | 2013-02-28 | 2021-11-01 | Caprion Proteomics Inc | Tuberkulosebiomarkører og anvendelser deraf |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
GB201310203D0 (en) | 2013-06-07 | 2013-07-24 | Electrophoretics Ltd | Materials and methods relating to Alzheimer's disease |
GB201310150D0 (en) * | 2013-06-07 | 2013-07-24 | Electrophoretics Ltd | Methods and compositions relating to alzheimer's disease |
US20160245828A1 (en) * | 2013-08-27 | 2016-08-25 | Crc For Mental Health Ltd | Method of Identifying Biomarkers of Neurological Diseases and Diagnosis of Neurological Diseases |
GB201322094D0 (en) | 2013-12-13 | 2014-01-29 | Electrophoretics Ltd | Methods and compositions relating to alzheimers disease |
WO2015103594A1 (en) * | 2014-01-06 | 2015-07-09 | Children's Medical Center Corporation | Biomarkers for dementia and dementia related neurological disorders |
GB201403489D0 (en) * | 2014-02-27 | 2014-04-16 | Univ London Queen Mary | Biomarkers for endometriosis |
AU2016243516A1 (en) * | 2015-03-27 | 2017-11-09 | The Research Foundation For The State University Of New York | Methods and materials for reducing amyloid beta levels within a mammal |
US9904961B2 (en) | 2015-05-07 | 2018-02-27 | Kuwait University | System and method for determining the feedback capacity of information distributed in a complex network |
JP6193942B2 (ja) * | 2015-09-09 | 2017-09-06 | 株式会社Mcbi | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
CN105403649B (zh) * | 2015-12-01 | 2018-03-20 | 深圳大学 | 一种检测ad的尿液多肽组ad生物标记物 |
JP6947451B2 (ja) * | 2016-06-29 | 2021-10-13 | 学校法人自治医科大学 | バイオマーカー、診断用組成物、及び診断用キット |
JP6947450B2 (ja) * | 2016-06-29 | 2021-10-13 | 学校法人自治医科大学 | バイオマーカー、診断用組成物、及び診断用キット |
US11592452B2 (en) * | 2017-07-14 | 2023-02-28 | Mcbi Inc. | Disease detection method |
JP6408087B2 (ja) * | 2017-07-25 | 2018-10-17 | 株式会社Mcbi | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
CN113024651A (zh) * | 2019-12-25 | 2021-06-25 | 中国医学科学院药物研究所 | 阿尔茨海默病生物标志物及其应用 |
US20220260559A1 (en) * | 2020-11-04 | 2022-08-18 | Seer, Inc. | Biomarkers for diagnosing alzheimer's disease |
WO2024083822A1 (en) * | 2022-10-18 | 2024-04-25 | Immungenetics Ag | Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia |
CN117831756A (zh) * | 2024-03-05 | 2024-04-05 | 精智未来(广州)智能科技有限公司 | 一种认知障碍的辅助分析方法、装置、设备及存储介质 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US6342350B1 (en) * | 1997-09-05 | 2002-01-29 | The General Hospital Corporation | Alpha-2-macroglobulin diagnostic test |
US20030211622A1 (en) * | 1998-06-29 | 2003-11-13 | Roberts L. Jackson | Methods and compositions to assess oxidative brain injury |
US20030131364A1 (en) * | 1999-04-27 | 2003-07-10 | Karen Duff | Method for producing transgenic animal models with modulated phenotype and animals produced therefrom |
JP2001249128A (ja) * | 2000-03-06 | 2001-09-14 | Ikagaku:Kk | 動脈硬化症またはアルツハイマー病の診断用キット |
US20020174447A1 (en) * | 2001-01-23 | 2002-11-21 | Greenspan Ralph J. | Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease |
US6528309B2 (en) * | 2001-03-19 | 2003-03-04 | The Regents Of The University Of California | Vacuum-mediated desiccation protection of cells |
US6451547B1 (en) * | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
DE10158180A1 (de) * | 2001-11-28 | 2003-09-11 | Biovision Ag | Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung |
WO2004001421A2 (en) * | 2002-06-21 | 2003-12-31 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
EP1572932A4 (de) * | 2002-07-03 | 2008-05-14 | Univ Illinois | Reagentien und verfahren zur identifizierung und modulation der expression von tumorseneszenzgenen |
DK1571970T3 (da) * | 2002-10-02 | 2011-11-28 | Dmi Biosciences Inc | Diagnose og monitorering af sygdomme |
KR100595494B1 (ko) * | 2003-02-24 | 2006-07-03 | (주) 디지탈바이오텍 | 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트 |
GB0421639D0 (en) * | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
-
2004
- 2004-09-29 GB GBGB0421639.6A patent/GB0421639D0/en not_active Ceased
-
2005
- 2005-09-29 AT AT05788728T patent/ATE495445T1/de not_active IP Right Cessation
- 2005-09-29 WO PCT/GB2005/003756 patent/WO2006035237A2/en active Application Filing
- 2005-09-29 JP JP2007534083A patent/JP5483816B2/ja active Active
- 2005-09-29 EP EP10010288.8A patent/EP2354795B1/de active Active
- 2005-09-29 EP EP12191625A patent/EP2562545A1/de not_active Withdrawn
- 2005-09-29 US US11/664,076 patent/US7897361B2/en active Active
- 2005-09-29 DK DK10010288.8T patent/DK2354795T3/en active
- 2005-09-29 AU AU2005288689A patent/AU2005288689B2/en active Active
- 2005-09-29 CA CA2580532A patent/CA2580532C/en active Active
- 2005-09-29 DE DE602005025897T patent/DE602005025897D1/de active Active
- 2005-09-29 EP EP05788728A patent/EP1794594B1/de active Active
-
2011
- 2011-01-12 US US13/005,121 patent/US20110165146A1/en not_active Abandoned
- 2011-06-08 JP JP2011128088A patent/JP5893269B2/ja active Active
-
2014
- 2014-08-05 JP JP2014159434A patent/JP2014209132A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20080070995A1 (en) | 2008-03-20 |
WO2006035237A2 (en) | 2006-04-06 |
US20110165146A1 (en) | 2011-07-07 |
EP2354795A1 (de) | 2011-08-10 |
JP2008514946A (ja) | 2008-05-08 |
JP2011209291A (ja) | 2011-10-20 |
JP2014209132A (ja) | 2014-11-06 |
EP2354795B1 (de) | 2014-12-17 |
DK2354795T3 (en) | 2015-02-16 |
JP5893269B2 (ja) | 2016-03-23 |
JP5483816B2 (ja) | 2014-05-07 |
CA2580532A1 (en) | 2006-04-06 |
WO2006035237A3 (en) | 2006-08-03 |
EP1794594A2 (de) | 2007-06-13 |
DE602005025897D1 (de) | 2011-02-24 |
AU2005288689A1 (en) | 2006-04-06 |
EP1794594B1 (de) | 2011-01-12 |
CA2580532C (en) | 2019-06-25 |
EP2562545A1 (de) | 2013-02-27 |
AU2005288689B2 (en) | 2011-10-27 |
GB0421639D0 (en) | 2004-10-27 |
US7897361B2 (en) | 2011-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE495445T1 (de) | Verfahren und zusammensetzungen in verbindung mit morbus alzheimer | |
NO20053855D0 (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
EP1841426A4 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit | |
ES2414872T8 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
EA200901373A1 (ru) | Аминогетероциклические соединения | |
EA201590833A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
EA200801481A1 (ru) | 5-(арилсульфонил)пиразолопиперидины | |
WO2006058868A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
IL177787A0 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
EA200401114A3 (ru) | Замещённые гидроксиэтиламины | |
WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
EA200601288A1 (ru) | Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение | |
WO2007058862A3 (en) | Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
ZA200702318B (en) | Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease | |
CY1110401T1 (el) | Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων | |
AU2003238046A1 (en) | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease | |
DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
WO2007019080A3 (en) | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
BRPI0509881A (pt) | combinação terapêutica para tratamento da doença de alzheimer | |
WO2007048034A3 (en) | Use of androgens for the treatment of parkinson' s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |